CRL
Charles River Laboratories
Charles River Laboratories historical holders
total: 7
Viking Global Investors Charles River Laboratories transactions over time
- Total transactions:
- 10
- New positions:
- 1
- Sold out:
- 1
- Added:
- 4
- Reduced:
- 4
- Held since:
- 2021 Q1
- Held for:
- 9 quarters
- Latest activity:
- 2023 Q2
Ole Andreas Halvorsen has been an institutional investor in Charles River Laboratories (CRL) since 2021 Q1. According to 2026 Q1 report, Ole Andreas Halvorsen doesn't hold any shares. The fund/company first acquired CRL in 2021 Q1, initially purchasing 448,716 shares. Since the initial investment, Viking Global Investors has made 9 more transactions in this position.
When did Ole Andreas Halvorsen exit their CRL position?
Ole Andreas Halvorsen no longer holds Charles River Laboratories (CRL). They sold off their entire position in 2023 Q2, closing out an investment that began in 2021 Q1.
When did Ole Andreas Halvorsen first invest in CRL?
Ole Andreas Halvorsen first invested in Charles River Laboratories (CRL) in 2021 Q1 at the reported quarter-end price of $289.83 per share, acquiring 448,716 shares in their initial purchase.
What is Ole Andreas Halvorsen's average cost basis for CRL?
Based on historical transaction data, Ole Andreas Halvorsen's estimated cost basis for Charles River Laboratories (CRL) is approximately $295.79 per share. This represents their average reported price* across all buy transactions.
Estimated cost basis*
- Weighted AVG buy price:
- $295.79
- Weighted AVG sell price:
- $261.37
CRL transactions history by Viking Global Investors
10 results
| Period |
% of portfolio |
Shares held after* |
Reported price* |
Value* |
% (shares) of activity |
% change to portfolio |
|---|---|---|---|---|---|---|
|
2023 Q2
|
0.00%
|
0
|
$201.82
|
|
-100% (-394,089)
|
-0.37%
|
|
2023 Q1
|
0.37%
|
394,089
|
$201.82
|
$79,535,042
|
-23.50% (-121,079)
|
-0.12%
|
|
2022 Q4
|
0.56%
|
515,168
|
$217.90
|
$112,255,107
|
-21.76% (-143,310)
|
-0.14%
|
|
2022 Q3
|
0.60%
|
658,478
|
$196.80
|
$129,588,000
|
+18.99% (+105,069)
|
+0.1%
|
|
2022 Q2
|
0.54%
|
553,409
|
$213.97
|
$118,413,000
|
+6.09% (+31,756)
|
+0.03%
|
|
2022 Q1
|
0.60%
|
521,653
|
$283.97
|
$148,134,000
|
+33.71% (+131,524)
|
+0.15%
|
|
2021 Q4
|
0.42%
|
390,129
|
$376.78
|
$146,993,000
|
+119.91% (+212,726)
|
+0.23%
|
|
2021 Q3
|
0.20%
|
177,403
|
$412.67
|
$73,209,000
|
-49.58% (-174,465)
|
-0.22%
|
|
2021 Q2
|
0.39%
|
351,868
|
$369.92
|
$130,163,000
|
-21.58% (-96,848)
|
-0.11%
|
|
2021 Q1
|
0.39%
|
448,716
|
$289.83
|
$130,051,000
|
new
|
+0.39%
|
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.